SM
ALNY icon

Sabby Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sabby Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-250
Closed -$2.98M – 145
2018
Q1 		$2.98M Sell
250
-1,353
-84% -$174K 0.35% 31
2017
Q4 		$20.4M Sell
1,603
-1,562
-49% -$196K 1.85% 12
2017
Q3 		$37.2M Buy
3,165
+774
+32% +$66.1K 2.43% 11
2017
Q2 		$19.1M Sell
2,391
-86
-3% -$5.5K 1.25% 14
2017
Q1 		$12.7M Buy
2,477
+421
+20% +$19.5K 0.68% 28
2016
Q4 		$7.7M Buy
2,056
+1,187
+137% +$49.7K 0.45% 37
2016
Q3 		$5.89M Buy
869
+263
+43% +$18.6K 0.22% 70
2016
Q2 		$3.36M Buy
+606
New +$38.2K 0.18% 72
2015
Q4 		– Sell
-789
Closed -$6.34M – 323
2015
Q3 		$6.34M Buy
789
+394
+100% +$43.8K 0.26% 64
2015
Q2 		$4.74M Buy
+395
New +$47.2K 0.17% 101
2014
Q4 		– Sell
-773
Closed -$6.04K – 242
2014
Q3 		$6.04K Sell
773
-303
-28% -$19.5K 0.23% 56
2014
Q2 		$6.8M Buy
+1,076
New +$64K 0.29% 50

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sabby Management's ALNY Position: Q2 2018 in Review

Sabby Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2018, closing a stake of 11,500 shares — an estimated $1.37M sold.

Sabby Management first reported a position in ALNY in Q2 2014 and held it in 5 quarters. The position peaked at $2.45M in Q4 2017. 310 funds tracked by Wall St. Rank hold ALNY as of Q2 2018.

  • Sabby Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Sabby Management sold 11,500 Alnylam Pharmaceuticals shares in Q2 2018, an estimated $1.37M.
  • Sabby Management first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 5 quarters.
  • Sabby Management's Alnylam Pharmaceuticals position peaked at $2.45M in Q4 2017.
  • 310 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.